All participants | Withdrawals | No withdrawals | ||
---|---|---|---|---|
N = 83 | N = 45 | N = 38 | p-valuea | |
Gender, female/maleb | 27/56 (33/67) | 15/30 (56/54) | 12/26 (44/46) | 0.865 |
Age, yearsc | 45 (9, 26–66) | 45 (9, 26–62) | 44 (10, 26–66) | 0.493 |
Methadone dose, mg/dayc | 97 (24, 20–170) | 101 (24, 35–170) | 92 (23, 20–150) | 0.079 |
Methadone serum concentration, ng/mLc | 374 (188, 74–1005) | 347 (168, 113–1005) | 405 (208, 74–998) | 0.145 |
CDR,d (ng/mL)/(mg/day)c | 4 (2, 1–11) | 3 (2, 1–11) | 4 (2, 1–9) | 0.039 |
Time since last dose, hoursc | 21 (8, 0–28) | 22 (5, 1–28) | 19 (10, 0–27) | 0.199 |
Duration of opioid agonist treatmentc | 9 (5, 1–20) | 9 (5, 1–18) | 9 (5, 1–20) | 0.922 |
Direct observed treatment, day/weekc | 4 (2, 1–7) | 4 (2, 1–7) | 3 (2, 1–6) | 0.026 |
Self-reported substance use last monthb | 73 (88) | 41 (92) | 32 (83) | 0.187 |
Heroinb | 10 (12) | 5 (12) | 5 (13) | 0.971 |
Other opioidsb | 5 (6) | 3 (6) | 2 (5) | 0.819 |
Benzodiazepinesb | 50 (62) | 29 (64) | 21 (55) | 0.233 |
Cannabisb | 55 (66) | 30 (65) | 25 (67) | 0.828 |
Amphetamineb | 26 (31) | 15 (33) | 11 (30) | 0.789 |
Alcoholb | 38 (46) | 22 (49) | 16 (42) | 0.542 |